Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2016', provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
- The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chemotherapy Induced Peripheral Neuropathy Overview 9
Therapeutics Development 10
Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Overview 10
Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis 11
Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Development by Companies 12
Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 14
Chemotherapy Induced Peripheral Neuropathy - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Chemotherapy Induced Peripheral Neuropathy - Products under Development by Companies 17
Chemotherapy Induced Peripheral Neuropathy - Products under Investigation by Universities/Institutes 18
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development 19
Achelios Therapeutics, Inc. 19
Amplyx Pharmaceuticals, Inc. 20
DermaXon, LLC 21
Eisai Co., Ltd. 22
Immune Pharmaceuticals Inc. 23
Kineta, Inc. 24
Laboratorios Del Dr. Esteve S.A. 25
MAKScientific, LLC 26
Mertiva AB 27
Midatech Pharma US Inc. 28
Nemus Bioscience, Inc. 29
Novartis AG 30
Panacea Pharmaceuticals, Inc. 31
PeriphaGen, Inc. 32
PharmatrophiX, Inc. 33
Spectrum Pharmaceuticals, Inc. 34
Virobay Inc. 35
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
(amitriptyline + ketamine hydrochloride) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AM-1710 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AXPN-02 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BR-297 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DX-0332 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
E-2072 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
E-52862 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
EMA-401 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Gene Therapy for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ketoprofen - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
KRN-5500 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
LM11A-31BHS - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
NRX-2922 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PAN-811 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PGN-503 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecule for Pain - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules to Agonize CB1 and CB2 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules to Inhibit FKBP52 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SPI-205 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
U-2902 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
VBY-036 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Chemotherapy Induced Peripheral Neuropathy - Recent Pipeline Updates 77
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects 84
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products 85
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones 86
Featured News & Press Releases 86
Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA 86
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 86
Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA 87
Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation 88
Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2016 10
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics, Inc., H1 2016 19
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016 20
Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon, LLC, H1 2016 21
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co., Ltd., H1 2016 22
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc., H1 2016 23
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta, Inc., H1 2016 24
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 25
Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific, LLC, H1 2016 26
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mertiva AB, H1 2016 27
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc., H1 2016 28
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience, Inc., H1 2016 29
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Novartis AG, H1 2016 30
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 31
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen, Inc., H1 2016 32
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX, Inc., H1 2016 33
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 34
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc., H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Assessment by Combination Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 41
Number of Products by Stage and Route of Administration, H1 2016 43
Number of Products by Stage and Molecule Type, H1 2016 45
Chemotherapy Induced Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H1 2016 77
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2016 84
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2016 85